| Total | 65-74 years | ≥ 75 years | P-value |
---|---|---|---|---|
Numbers | 287 | 118 | 169 | Â |
Age (years), mean (SD) | 76.8 (7.1) | 70.1(3.1) | 81.6 (4.9) | < 0.001 |
BMI, mean (SD) | 21.6 (3.5) | 21.4 (3.5) | 21.6 (3.6) | 0.64 |
< 18.5, n (%) | 59 (20.6) | 20 (16.9) | 39 (23.1) | 0.13 |
18.5 − 25, n (%) | 188 (65.5) | 85 (72.0) | 103 (60.9) | |
25 − 30, n (%) | 35 (12.2) | 10 (8.5) | 25 (14.8) | |
> 30, n (%) | 5 (1.7) | 3 (2.5) | 2 (1.2) | |
Height (cm), mean (SD) | 150.1 (6.3) | 152.2 (6.2) | 148.7 (6.0) | < 0.001 |
Weight (kg), mean (SD) | 48.5 (8.1) | 49.5 (7.6) | 47.8 (8.3) | 0.08 |
Waist circumference (cm), mean (SD) | 80.4 (10.0) | 79.5 (9.9) | 80.9 (10.1) | 0.26 |
Trunk fat (%), mean (SD) | 30.2 (8.4) | 30.8 (8.1) | 29.7(8.6) | 0.29 |
Anti-osteoporotic drugs | Â | Â | Â | Â |
Any, n (%) | 269 (93.7) | 110 (93.2) | 156 (92.3) | 0.77 |
SERM, n (%) | 73 (25.4) | 42 (35.6) | 31(18.3) | < 0.05 |
Bisphosphonate, n (%) | 121 (42.2) | 45 (38.1) | 31(18.3) | |
Denosumab, n (%) | 56 (19.5) | 17 (14.4) | 39 (23.1) | |
Teriparatide, n (%) | 5 (1.7) | 1 (0.8) | 4 (2.4) | |
Anti-sclerostin Antibody, n (%) | 5 (1.7) | 1 (0.8) | 4 (2.4) | |
Fractur any, n (%) | 170 (59.2) | 49 (41.5) | 121 (71.6) | < 0.001 |
Fractur spine, n (%) | 164 (57.1) | 46 (39.0) | 118 (69.8) | < 0.001 |
Fractur hip, n (%) | 9 (3.1) | 3 (2.5) | 6 (3.6) | 0.63 |
SAD (mm), mean (SD) | 162.4 (25.5) | 156.2 (24.1) | 166.7 (25.6) | < 0.001 |
CCI (points), Median [IQR] | 0 [0 − 2] | 0 [0 − 2] | 0 [0 − 2] | 0.24 |
Bone Mineral Density (Spine; g/cm2), Median [IQR] | 0.789 [0.688 − 0.895] | 0.764 [0.676 − 0.875] | 0.812 [0.706 − 0.944] | < 0.05 |
Bone Mineral Density (Hip neck; g/cm2), mean (SD) | 0.528 (0.093) | 0.535 (0.091) | 0.524 (0.095) | 0.34 |
Bone Mineral Density (Hip neck; T score), mean (SD) | -2.8 (3.5) | -2.6 (2.1) | -2.9 (4.3) | 0.40 |
Hand grip (kg), mean (SD) | 18.8 (4.6) | 20.6 (3.6) | 17.6 (4.7) | < 0.001 |
2 Step, Median [IQR] | 1.25 [1.09 − 1.37] | 1.35 [1.20 − 1.46] | 1.18 [0.98 − 1.30] | < 0.001 |
3 m Timed Up and Go test (s), Median [IQR] | 7.2 [6.0 − 9.0] | 6.4 [5.5 − 7.6] | 8.1 [6.6 − 10.5] | < 0.001 |
Open eye unipedal standing (s), Median [IQR] | 15.0 [4.8 − 15.0] | 15.0 [15.0 − 15.0] | 7.0 [2.9 − 15.0] | < 0.001 |
Rise 40 cm clear | 37 (12.9) | 4 (3.4) | 33 (19.5) | < 0.001 |
Rise 30Â cm clear | 26 (9.1) | 7 (5.9) | 19 (11.2) | |
Rise 20Â cm clear | 66 (23.0) | 22 (18.6) | 44 (26.0) | |
Rise 10Â cm clear | 140 (48.8) | 82 (69.5) | 58 (34.3) | |
Starts up, 40Â m not possible. | 14 (4.9) | 2 (1.7) | 12 (7.1) | |
Startup unchecked | 4 (1.4) | 1 (0.8) | 3 (1.8) | |
VAS (lumber), Median [IQR] | 2.0 [0.0 − 3.0] | 2.0 [0.0 − 3.0] | 2.5 [0.0 − 4.0] | < 0.01 |
PT (°), mean (SD) | 21.5 (10.7) | 19.1(9.3) | 23.2(11.3) | < 0.01 |
SVA (mm), Median [IQR] | 19.3 [-16.9 − 42.4] | 29.8 [9.3 − 57.9] | 55.0 [29.0 − 93.9] | < 0.001 |
SS (°), mean (SD) | 29.4 (10.0) | 30.7(8.6) | 28.4 (10.7) | < 0.05 |
Has an exercise habit(%) | 155 (54.0) | 66 (58.9) | 89 (56.3) | 0.67 |
Has had a fall in the past year(%) | 61 (21.3) | 23 (19.5) | 38 (22.5) | 0.48 |
Fall risk (points), mean (SD) | 4.7 (3.4) | 3.6 (3.1) | 5.5 (3.4) | < 0.001 |